Last reviewed · How we verify
NCT04937335
Craniopharyngioma With Tumoral Hemorrhage
trial testing intratumoral hemorrhage in Craniopharyngioma in 185 participants. Completed in 1 February 2021.
1 February 2021
Quick facts
| Lead sponsor | Tongji Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 185 |
| Start date | 1 January 2013 |
| Primary completion | 1 February 2021 |
| Estimated completion | 1 February 2021 |
Drugs / interventions tested
- intratumoral hemorrhage
Conditions studied
- Craniopharyngioma — all drugs for Craniopharyngioma →
- Apoplexy — all drugs for Apoplexy →
Sponsor
Tongji Hospital
Who can join
Eligibility, any sex, with Craniopharyngioma or Apoplexy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinical data of 185 consecutive patients receiving resective operation with a pathological diagnosis of craniopharyngioma in our hospital between January 2013 and February 2021 were collected. Among these patients, 18 of them were recognized as craniopharyngioma with tumoral hemorrhage during the operation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04937335
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Craniopharyngioma
Currently open trials in the same condition.
- NCT07177482 — ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients · NA · recruiting
- NCT06801756 — Craniopharyngioma and Pregnancies · recruiting
- NCT06299891 — Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity · Phase 2 · recruiting
- NCT05525273 — Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma · Phase 2 · recruiting
- NCT05465174 — Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults · Phase 2 · recruiting
Other Tongji Hospital trials
Trials by the same sponsor.
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
- NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
- NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04937335 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
- Last refreshed: 24 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04937335.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing